Advanced basal cell carcinoma: What dermatologists need to know about treatment

Wilson, Melissa; Johnson, Ryan P.; Senft, Stephen C.; Pan, Eva Y; Krakowski, Andrew C.

doi:10.1016/j.jaad.2022.03.022

Cited by 11 publications

(13 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For instance, itraconazole inhibits the Hedgehog pathway at the level of SMO. Arsenic trioxide inhibits GLI transcriptional activity [ 74 ].…”

Section: Discussionmentioning

confidence: 99%

“…Within 1 year he achieved complete remission, which has been durable for over 6 years and is ongoing. Republished from [76] with permission from Springer Nature management of advanced/metastatic BCCs [73][74][75].…”

Section: Basal Cell Carcinoma (Bcc)mentioning

confidence: 99%

“…Advanced and metastatic BCCs have several unique features. In particular, they often have high tumor mutational burdens; there are also case reports of programmed death-ligand 1 (PD-L1) gene amplification [73][74][75]. These molecular features sensitize to immune checkpoint blockade with programmed cell death protein 1 (PD1)/PD-L1 inhibitors.…”

Section: Basal Cell Carcinoma (Bcc)mentioning

confidence: 99%

“…Republished from [77] with permission from MDPI (Multidisciplinary Digital Publishing Institute), Barcelona, Spain immunotherapy is also a treatment option for patients with advanced and metastatic BCCs [73,75,76,78]. Currently, cemiplimab-a PD1 inhibitor-is the only FDA-approved immunotherapy agent for Hedgehog inhibitorresistant advanced and metastatic BCCs [74,78,79]. However, there are several reports of other anti-PD1 agents (such as nivolumab or pembrolizumab) that have been successfully used to treat advanced (Figs.…”

Section: Basal Cell Carcinoma (Bcc)mentioning

confidence: 99%

See 3 more Smart Citations

Dermatologic Disease-Directed Targeted Therapy (D3T2): The Application of Biomarker-Based Precision Medicine for the Personalized Treatment of Skin Conditions—Precision Dermatology

Cohen

Kurzrock

2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Precision dermatology uses individualized dermatologic disease-directed targeted therapy (D 3 T 2 ) for the management of dermatoses and for the evaluation and therapy of cutaneous malignancies. Personalized/precision strategies are based on biomarkers that are most frequently derived from tissue transcriptomic expression or genomic sequencing or from circulating cytokines. For instance, the pathologic diagnosis of a pigmented lesion and determining the prognosis of a malignant melanocytic neoplasm can be enhanced by genomic/transcriptomic analysis. In addition to biopsy, innovative techniques have been developed for

show abstract

“…For instance, itraconazole inhibits the Hedgehog pathway at the level of SMO. Arsenic trioxide inhibits GLI transcriptional activity [ 74 ].…”

Section: Discussionmentioning

confidence: 99%

Section: Basal Cell Carcinoma (Bcc)mentioning

confidence: 99%

Section: Basal Cell Carcinoma (Bcc)mentioning

confidence: 99%

Section: Basal Cell Carcinoma (Bcc)mentioning

confidence: 99%

See 2 more Smart Citations

Dermatologic Disease-Directed Targeted Therapy (D3T2): The Application of Biomarker-Based Precision Medicine for the Personalized Treatment of Skin Conditions—Precision Dermatology

Cohen

Kurzrock

2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“… 1 Fortunately, BCC is highly curable and unlikely to metastasize. 2 Treatment options include topical agents (imiquimod and 5-fluorouracil), photodynamic therapy, surgical removal including Mohs micrographic surgery, and radiotherapy. 3 Metastatic and/or locally advanced tumours, hereby termed advanced basal cell carcinoma (aBCC), represent 1%–10% of BCC cases, 4 and can be challenging to treat due to tumour factors such as size, extent of invasion, anatomical location, and/or expected morbidity or mortality with conventional surgery or radiotherapy.…”

Section: Introductionmentioning

confidence: 99%

Combined cemiplimab and radiotherapy for advanced basal cell carcinoma: A case report

Sarfaraz

Hayes

Hunt

2023

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

Advanced basal cell carcinoma may be treated with systemic therapies such as hedgehog pathway inhibitors or programmed cell death protein 1 inhibitors, namely cemiplimab. We report a case of a 70-year-old man with a nodulo-infiltrative advanced basal cell carcinoma over the right posterior neck and scapula. The patient had a partial response to the hedgehog pathway inhibitor, vismodegib. The tumour progressed, and the patient was switched from vismodegib to radiotherapy combined with cemiplimab, which led to a significant reduction in pain, bleeding, and tumour size. A combined treatment approach with radiotherapy and cemiplimab may be beneficial for advanced basal cell carcinoma cases that progress after treatment with hedgehog pathway inhibitors.

show abstract

Identification of tumour‐infiltrating myeloid subsets associated with overall survival in lung squamous cell carcinoma

Duan

Liu

et al. 2022

The Journal of Pathology

View full text Add to dashboard Cite

Lung squamous cell carcinoma (LUSC) is a primary subtype of lung cancer with limited therapeutic options and poor prognosis, and tumour‐infiltrating myeloid cells (TIMs) are key regulators of LUSC. However, the correlation between the abundance of TIM subtypes and clinical outcomes of LUSC remains unexplored. This study aimed to develop and validate a prognostic model for low‐ and high‐risk patients with LUSC based on myeloid cell microenvironments. TIM markers in the tumoural (T) and stromal (S) regions were quantified using immunohistochemistry for 502 LUSC patients. L1‐penalized Cox regression was used to develop a myeloid survival score (MSS) model based on the training cohort, followed by validation in distinct cohorts from multiple centres. RNA sequencing and immunostaining were used to examine the mechanisms of myeloid cells in LUSC progression and predict potential drug targets and therapeutic agents. Of the 12 myeloid markers, CD163T, CD163S, and S100A12T were highly associated with overall survival (OS) in LUSC patients. The MSS of the three myeloid signatures accurately categorized LUSC patients into risk categories, with an observable difference in OS between the training and validation cohorts. Tumours with high MSS were associated with enhanced antioxidative ability and hedgehog signalling and a shift to a more pro‐tumorigenic microenvironment, accompanied by a reduced tumour cell immunogenicity and increased CD8+ T cell exhaustion patterns. Additionally, in high‐risk patients, potential drug targets and compounds regulating hedgehog signalling were identified. Our study provides the first prognostic myeloid signature for LUSC, which may help advance precision medicine. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

show abstract

Advanced basal cell carcinoma: What dermatologists need to know about treatment

Cited by 11 publications

References 38 publications

Dermatologic Disease-Directed Targeted Therapy (D3T2): The Application of Biomarker-Based Precision Medicine for the Personalized Treatment of Skin Conditions—Precision Dermatology

Dermatologic Disease-Directed Targeted Therapy (D3T2): The Application of Biomarker-Based Precision Medicine for the Personalized Treatment of Skin Conditions—Precision Dermatology

Combined cemiplimab and radiotherapy for advanced basal cell carcinoma: A case report

Identification of tumour‐infiltrating myeloid subsets associated with overall survival in lung squamous cell carcinoma

Contact Info

Product

Resources

About